Alan Lin Huang

6884782, Apr 26, 2005

Nov 7, 2001

10/008244

Alan Huang - San Mateo CA, US
Jiwen Liu - Belmont CA, US
Julio Medina - San Carlos CA, US
Xuemei Wang - San Bruno CA, US
Feng Xu - Palo Alto CA, US
Liusheng Zhu - Burlingame CA, US

Amgen Inc. - Thousand Oaks CA

C07K005/06

514 19, 549200, 548535

The present invention provides compounds, compositions and methods for the inhibition or treatment of conditions or disorders modulated by the STAT transcription factors, particularly STAT4 and STAT6. Additionally, the compounds are useful for the diagnosis of conditions dependent on STAT signaling.

6964967, Nov 15, 2005

Dec 11, 2001

10/015532

Alan Xi Huang - San Mateo CA, US
Michael G. Johnson - San Francisco CA, US
Jiwen Liu - Belmont CA, US
Julio C. Medina - San Carlos CA, US

Amgen, Inc. - Thousand Oaks CA

C07D471/04
A61K031/519

5142641, 544279

Compounds having the formula:.

7053215, May 30, 2006

Aug 29, 2002

10/231895

Julio C. Medina - San Carlos CA, US
Michael G. Johnson - San Francisco CA, US
Jiwen Liu - Belmont CA, US
Alan Xi Huang - San Mateo CA, US
Liusheng Zhu - Burlingame CA, US
Andrew P. Marcus - San Francisco CA, US

Amgen SF, LLC - South San Francisco CA

C07D 403/12
A61K 31/517

544284, 5142662, 51426623

Compounds are provided that have the formula:.

7067662, Jun 27, 2006

Sep 21, 2004

10/946935

Julio C. Medina - San Carlos CA, US
Michael G. Johnson - San Francisco CA, US
Jiwen Liu - Belmont CA, US
Alan Xi Huang - San Mateo CA, US
Liusheng Zhu - Burlingame CA, US
Andrew P. Marcus - San Francisco CA, US

Amgen SF, LLC - South San Francisco CA

C07D 239/70

544282, 544253

Compounds, compositions and methods that are useful in the treatment of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.

7144903, Dec 5, 2006

May 22, 2002

10/155605

Tassie Collins - San Mateo CA, US
Hossen Mahmud - San Antonio TX, US
Jonathan Houze - San Mateo CA, US
Alan Xi Huang - San Mateo CA, US
Julio C. Medina - San Carlos CA, US
Xuemei Wang - San Mateo CA, US
Feng Xu - Palo Alto CA, US
Qingge Xu - Burlingame CA, US
Liusheng Zhu - Burlingame CA, US

Amgen Inc. - Thousand Oaks CA

C07D 417/12
C07D 419/12
C07D 401/00
A61K 31/425

514365, 548181, 544137, 546209

Compounds, compositions and methods are provided that are useful in the treatment of chemokine receptor-mediated conditions and diseases. In particular, the invention provides compounds which modulate CCR4 function or a CCR4-mediated response. The subject compounds and compositions are useful for the treatment or prevention of inflammatory conditions and diseases.

7231109, Jun 12, 2007

May 28, 2006

11/420762

Alan Huang - Menlo Park CA, US

G02B 6/28

385 24, 385 16, 398 79, 398 82, 398102

The electronic-to-optical multiplexer takes n electronic inputs Xwhere i=0 to n−1; converts Xinto optical signals Yeach with a different wavelength; wavelength multiplexes Y; samples Ywith an optical frame sync signal having a period of n*p seconds and a pulse width w; wavelength demultiplexes Y; staggers Yby i*p seconds; wavelength multiplexes Y; gates an optical clock signal with Y; and uses the gated optical clock signal as the optical output. The optical-to-electronic demultiplexer takes n optical sources Zeach with a different wavelength; wavelength multiplexes Z; gates Zwith the input of the optical-to-electronic demultiplexer; wavelength demultiplexes Z; staggers Zby (n−i)*p seconds; wavelength multiplexes Z; gates Zwith the frame sync signal delayed by (n−1)*p seconds; wavelength demultiplexes Z; detects Zwith detectors DECT; and uses the output of DECTas the electronic outputs.

7393601, Jul 1, 2008

Aug 5, 2004

10/911500

Charles Changqing Chen - Milpitas CA, US
Shoutao Wang - Fremont CA, US
Alan Huang - San Jose CA, US

Seagate Technology LLC - Scotts Valley CA

G11B 5/66
G11B 5/70

428828, 427131

A magnetic recording medium having a substrate, underlayer, a low moment stabilizing layer, an antiferromagnetic coupling layer, a low magnetic layer having a magnetic saturation of equal to or less than 250 emu/cm, and a high moment magnetic layer having a magnetic saturation of more than 250 emu/cm, in this order, is disclosed. The magnetic recording medium has a weak coupling strength of Jex ≦0. 05.

7470724, Dec 30, 2008

Apr 26, 2004

10/833295

Carina Cannizzaro - San Mateo CA, US
James M. Chen - San Ramon CA, US
Xiaowu Chen - San Mateo CA, US
Aesop Cho - Mountain View CA, US
Lee S. Chong - Newark CA, US
Manoj Desai - Pleasant Hill CA, US
Maria Fardis - San Carlos CA, US
Alan X. Huang - San Mateo CA, US
Thorsten Kirschberg - Belmont CA, US
Christopher P. Lee - San Francisco CA, US
Richard L. Mackman - Millbrae CA, US
Peter H. Nelson - Los Altos CA, US
Hyung-Jung Pyun - Freemont CA, US
Adrian S. Ray - San Mateo CA, US
William J. Watkins - Sunnyvale CA, US
Jennifer R. Zhang - Foster City CA, US
Sundaramoorthi Swaminathan - Burlingame CA, US

Gilead Sciences, Inc. - Foster City CA

A61K 31/27

514470, 549462

The invention is related to phosphonate substituted compounds having immuno-modulatory activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.